HPV相关口咽癌患者术后ctHPVDNA动力学
这项前瞻性队列研究在单中心纳入57例可检出治疗前TTMV HPV DNA的HPV相关口咽鳞状细胞癌手术患者,于术前、术后第1至2天和术后约第2周采血检测。术后第1至2天可检出者占28%,其与术前水平呈中度正相关;术后第1至2天检测阴性对第2周阴性有较高阴性预测值,但阳性预测值较低。
要点
- 术后第1至2天可检出TTMV HPV DNA者占28%(16/57)。
- 术后第1至2天阴性的阴性预测值为0.95,阳性预测值仅0.19。
- 术后早期检出情况不能预测术后第2周是否可检出。
核心结论
- 术后早期ctHPVDNA可检出性不能预测术后2周的可检出性。
- 术后早期ctHPVDNA清除可预测2周时检测阴性。
- 术后第1天采血阴性或可在未来临床试验中用于免去术后2周的微小残留病灶检测采血。
研究设计与样本
- 前瞻性队列研究,于2020年1月4日至2023年1月26日在单家三级医疗中心开展。
- 纳入新诊断并接受手术治疗的HPV相关口咽鳞状细胞癌患者;排除既往头颈癌史及初诊时转移性疾病者。
- 共57例治疗前可检出TTMV HPV DNA的患者,其中51例(89%)为男性,中位(IQR)年龄59(54-66)岁。
- 35例(61%)在全部3个时间点采血;16例(28%)在术后第1至2天可检出TTMV HPV DNA。
- 暴露为经口机器人手术联合颈部淋巴结清扫;数据分析时间为2024年9月1日至2025年4月25日。
主要发现
- 术前与术后第1至2天TTMV HPV DNA水平呈中度正线性相关(r=0.31;95%CI,0.04-0.54)。
- 术后第1至2天采血未检出TTMV HPV DNA对术后第2周未检出的阴性预测值为0.95(95%CI,0.74-1.00)。
- 术后第1至2天采血可检出TTMV HPV DNA对第2周可检出的阳性预测值仅为0.19(95%CI,0.04-0.46)。
- 术前及术后第1至2天均可检出的16例中,仅3例(19%)在术后第2周仍可检出。
- 1例患者在术后第1至2天未检出而术后第2周可检出。
关键数值与推荐
- HPV阳性定义为p16免疫组化、HPV DNA原位杂交、E6/E7 RNA原位杂交中任一阳性。
- 采血时间点为术前、术后第1至2天及术后第2周(范围8至20天)。
- ctHPVDNA采用肿瘤组织修饰病毒(TTMV)HPV DNA检测定量。
- 术前与术后第1至2天TTMV HPV DNA水平的相关性采用高斯回归检验。
- 术后第1至2天与第2周可检出性的一致性采用阴性预测值和阳性预测值评估。
临床怎么用
- 作者认为,术后第1天采血阴性或可在未来临床试验中用于免去术后2周的微小残留病灶检测采血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Circulating tumor human papillomavirus DNA (ctHPVDNA) is an important biomarker for the presence of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but little is known about early postoperative kinetics of ctHPVDNA clearance. OBJECTIVE: To investigate early postoperative kinetics of ctHPVDNA in patients with HPV-associated OPSCC. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at a single tertiary care center from January 4, 2020, to January 26, 2023. Patients with newly diagnosed HPV-associated OPSCC undergoing surgical management were enrolled. HPV status was defined as positive if findings of p16 immunohistochemistry and/or HPV DNA in situ hybridization and/or E6/E7 RNA in situ hybridization were positive. Exclusion criteria included history of prior head and neck cancer and metastatic disease at presentation. Data were analyzed from September 1, 2024, to April 25, 2025. EXPOSURES: Transoral robotic surgery with concurrent neck dissection. MAIN OUTCOMES AND MEASURES: Blood was drawn prior to surgery (pretreatment), 1 to 2 days after surgery (postoperative days 1 to 2), and approximately 2 weeks after surgery (postoperative week 2; range, 8 to 20 days). ctHPVDNA was quantified by a tumor tissue-modified viral (TTMV) HPV DNA test. Correlations were tested between the pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels using Gaussian regression. Concordance between detectability at postoperative day 1 to 2 and postoperative week 2 was explored using negative predictive value and positive predictive value. RESULTS: Of 57 included patients with detectable pretreatment TTMV HPV DNA, 51 (89%) were male, and the median (IQR) age was 59 (54-66) years. A total of 35 patients (61%) had blood draws at all 3 time points; 16 (28%) had detectable TTMV HPV DNA on postoperative day 1 to 2. Pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels had a medium positive linear correlation (r = 0.31; 95% CI, 0.04-0.54). Undetectable TTMV HPV DNA on postoperative day 1 to 2 blood draw had a negative predictive value of 0.95 (95% CI, 0.74-1.00) for an undetectable level on postoperative week 2 blood draw, but a detectable level on postoperative day 1 to 2 blood draw only had a positive predictive value of 0.19 (95% CI, 0.04-0.46). Of the 16 patients with detectable TTMV HPV DNA pretreatment and at postoperative day 1 to 2, only 3 (19%) continued to have detectable TTMV HPV DNA at postoperative week 2. One patient had undetectable levels at postoperative day 1 to 2 and detectable levels at postoperative week 2. CONCLUSIONS AND RELEVANCE: In this study, ctHPVDNA detectability early after surgery did not predict detectability at 2 weeks after surgery. ctHPVDNA clearance early after surgery could predict a negative test at 2 weeks. A negative blood draw finding on postoperative day 1 may be used to omit a postoperative blood draw at 2 weeks for minimal residual disease detection in future clinical trials.
引用
- Yin LX, Hidalgo CM, Bogan AW, et al. Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40367049. doi:10.1001/jamaoto.2025.1606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。